Nektar Therapeutics - NKTR Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Reduce
Consensus Price Target: $3.00
Forecasted Upside: 398.50%
Number of Analysts: 5
Breakdown:
1 Sell Ratings
4 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$0.60 As of 09/27/2023 01:00 AM ET

▼ -0.01 (-1.63%)

1 month | 3 months | 12 months

Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

^$3.00

▲ +398.50% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 398.50% upside from the last price of $0.60.

Current Consensus is Reduce

The current consensus among 5 contributing investment analysts is to reduce stock in Nektar Therapeutics. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/5/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

7/4/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

10/2/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

12/31/2022

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

3/31/2023

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/29/2023

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

8/28/2023

0 strong buy ratings
0 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

9/27/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/7/2023	Mizuho	Reiterated Rating	Neutral	$6.00	Low
5/10/2023	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$1.50 ➝ $1.00	Low
3/6/2023	Oppenheimer	Lower Target	Market Perform	$5.00 ➝ $3.00	Low
2/27/2023	The Goldman Sachs Group	Lower Target	Sell	$3.00 ➝ $2.00	Low
2/24/2023	SVB Securities	Lower Target		$5.00 ➝ $3.00	N/A
2/24/2023	SVB Leerink	Lower Target	Market Perform	$5.00 ➝ $3.00	N/A
2/24/2023	Jefferies Financial Group	Downgrade	Hold ➝ Underperform	$3.20 ➝ $1.50	N/A
8/8/2022	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Low
4/20/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Medium
4/18/2022	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$3.00	High
4/18/2022	SVB Leerink	Lower Target	Market Perform	$7.00 ➝ $6.00	High
4/18/2022	Mizuho	Lower Target	Neutral	$8.00 ➝ $6.00	Low
3/16/2022	Canaccord Genuity Group	Lower Target	Buy	$25.00 ➝ $6.00	High
3/15/2022	SVB Leerink	Lower Target	Market Perform	$18.00 ➝ $7.00	High
3/15/2022	Mizuho	Downgrade	Buy ➝ Neutral	$35.00 ➝ $8.00	High
3/14/2022	Cowen	Downgrade	Outperform ➝ Market Perform	$35.00 ➝ $8.00	High
3/14/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
3/14/2022	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$24.00 ➝ $5.00	High
3/14/2022	BTIG Research	Downgrade	Buy ➝ Neutral		High
3/14/2022	William Blair	Downgrade	Outperform ➝ Market Perform		High
3/14/2022	Bank of America	Downgrade	Neutral ➝ Underperform	$18.00 ➝ $6.00	High
3/9/2022	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$21.00	Medium
3/1/2022	JPMorgan Chase & Co.	Lower Target		$24.00 ➝ $17.00	High
11/8/2021	BTIG Research	Lower Target	Positive ➝ Buy	$80.00 ➝ $54.00	High
11/8/2021	SVB Leerink	Lower Target	Market Perform	$19.00 ➝ $18.00	High
11/8/2021	Benchmark	Upgrade	Hold ➝ Buy	$20.00	High
11/5/2021	Oppenheimer	Lower Target	Market Perform	$25.00 ➝ $21.00	High
9/10/2021	Bank of America	Initiated Coverage	Neutral	$18.00	Low
8/6/2021	SVB Leerink	Lower Target	Market Perform	$20.00 ➝ $19.00	Low
6/28/2021	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$22.00 ➝ $24.00	Medium
5/10/2021	SVB Leerink	Lower Target	Market Perform	$21.00 ➝ $20.00	Low
5/7/2021	Mizuho	Reiterated Rating	Buy		High
4/6/2021	SVB Leerink	Boost Target	Market Perform	$20.00 ➝ $21.00	Low
3/1/2021	Benchmark	Reiterated Rating	Buy ➝ Hold	$26.00	Low
2/22/2021	Benchmark	Downgrade	Buy ➝ Hold	$26.00	High
1/5/2021	Stifel Nicolaus	Initiated Coverage	Hold	$18.00	N/A
11/12/2020	SVB Leerink	Boost Target	Market Perform	$17.00 ➝ $20.00	Low
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$26.00	High
8/14/2020	SVB Leerink	Lower Target	Market Perform	$18.00 ➝ $17.00	Medium
8/7/2020	Oppenheimer	Reiterated Rating	Hold	$25.00	High
6/10/2020	Cfra	Downgrade	Hold ➝ Sell		Low
5/26/2020	Mizuho	Initiated Coverage	Buy	$35.00	Low
5/18/2020	Oppenheimer	Boost Target	Market Perform	$24.00 ➝ $25.00	Medium
5/12/2020	HC Wainwright	Lower Target	Neutral	$32.00 ➝ $26.00	High
5/8/2020	SVB Leerink	Boost Target	Market Perform	$17.00 ➝ $18.00	High
4/22/2020	Benchmark	Initiated Coverage	Buy	$26.00	Medium
4/2/2020	Mizuho	Reiterated Rating	Buy	$35.00	High
3/30/2020	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$18.00 ➝ $20.00	Low
3/9/2020	JPMorgan Chase & Co.	Lower Target	Neutral	$28.00 ➝ $27.00	High
3/4/2020	Barclays	Initiated Coverage	Overweight	$30.00	High
2/28/2020	Piper Sandler	Reiterated Rating	Buy	$35.00	High
2/28/2020	BTIG Research	Lower Target	Buy	$101.00 ➝ $80.00	High
2/28/2020	William Blair	Reiterated Rating	Outperform		High
2/28/2020	Cowen	Reiterated Rating	Buy	$27.00	Low
2/12/2020	Cowen	Reiterated Rating	Buy	$30.00	Medium
2/3/2020	Mizuho	Reiterated Rating	Neutral ➝ Buy	$21.00 ➝ $35.00	High
1/10/2020	Mizuho	Initiated Coverage	Hold	$21.00	High
1/10/2020	HC Wainwright	Reiterated Rating	Hold	$32.00	High
11/11/2019	HC Wainwright	Boost Target	Neutral	$24.00 ➝ $32.00	High
11/7/2019	Piper Jaffray Companies	Lower Target	Overweight	$50.00 ➝ $35.00	High
11/7/2019	Cowen	Reiterated Rating	Buy		High
11/7/2019	Mizuho	Reiterated Rating	Hold	$21.00	High
10/24/2019	Oppenheimer	Initiated Coverage	Market Perform	$18.00	Medium
10/8/2019	The Goldman Sachs Group	Downgrade	Buy ➝ Sell	$54.00 ➝ $16.00	High
9/30/2019	HC Wainwright	Set Target	Hold	$24.00	High
9/26/2019	Cowen	Set Target	Buy	$43.00	Medium
9/26/2019	William Blair	Reiterated Rating	Buy		Medium
9/26/2019	Piper Jaffray Companies	Set Target	Buy	$50.00	Medium
8/13/2019	HC Wainwright	Reiterated Rating	Hold		Medium
8/11/2019	Evercore ISI	Reiterated Rating	Hold	$37.00	High
8/9/2019	William Blair	Reiterated Rating	Buy		Low
8/9/2019	Cfra	Set Target	Hold	$35.00	Low
8/9/2019	BMO Capital Markets	Lower Target	Outperform	$75.00 ➝ $41.00	High
8/9/2019	Mizuho	Downgrade	Buy ➝ Neutral	$79.00 ➝ $21.00	High
8/9/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$62.00 ➝ $33.00	High
8/9/2019	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$59.00 ➝ $23.00	High
8/9/2019	Piper Jaffray Companies	Boost Target	Overweight	$50.00 ➝ $100.00	High
7/26/2019	Mizuho	Lower Target	Buy	$81.00 ➝ $79.00	High
6/14/2019	William Blair	Reiterated Rating	Buy		Medium
6/13/2019	Cowen	Set Target	Buy	$82.00	Medium
6/4/2019	William Blair	Reiterated Rating	Buy		Medium
6/2/2019	Cowen	Set Target	Buy	$82.00	High
5/24/2019	Mizuho	Reiterated Rating	Buy	$81.00	Low
3/15/2019	SVB Leerink	Initiated Coverage	Mkt Perform	$38.00	Medium
3/4/2019	HC Wainwright	Reiterated Rating	Hold	$47.00	Low
3/1/2019	Piper Jaffray Companies	Set Target	Buy	$100.00	Low
3/1/2019	Mizuho	Reiterated Rating	Buy	$81.00	High
2/22/2019	BMO Capital Markets	Initiated Coverage	Outperform	$75.00	Medium
2/19/2019	Mizuho	Reiterated Rating	Buy		Low
2/19/2019	HC Wainwright	Reiterated Rating	Hold	$47.00	Low
1/23/2019	Mizuho	Reiterated Rating	Buy	$81.00 ➝ $81.00	Low
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Buy	$81.00 ➝ $62.00	High
11/12/2018	HC Wainwright	Set Target	Hold	$47.00	High
11/8/2018	Cowen	Reiterated Rating	Buy	$86.00	High
11/8/2018	Jefferies Financial Group	Lower Target	Buy ➝ Buy	$103.00 ➝ $73.00	High
11/5/2018	HC Wainwright	Reiterated Rating	Hold	$47.00	Medium
10/22/2018	HC Wainwright	Set Target	Hold	$54.00	High

(Data available from 9/27/2018 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
9 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

3/1/2023

7 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/31/2023

1 very positive mentions
10 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/30/2023

2 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/30/2023

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/29/2023

4 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/29/2023

7 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

8/28/2023

3 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/27/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $0.60

$0.59

$0.62

50 Day Range

MA: $0.66

$0.51

$1.05

52 Week Range

Now: $0.60

$0.51

$4.37

Volume

484,328 shs

Average Volume

4,804,837 shs

Market Capitalization

$114.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?: The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: Jefferies Financial Group Inc., Mizuho, Oppenheimer Holdings Inc., StockNews.com, SVB Leerink LLC, SVB Securities, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for NKTR.
What is the current price target for Nektar Therapeutics?: 6 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 398.5%. Mizuho has the highest price target set, predicting NKTR will reach $6.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $1.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.
What is the current consensus analyst rating for Nektar Therapeutics?: Nektar Therapeutics currently has 1 sell rating and 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for NKTR.
What other companies compete with Nektar Therapeutics?: Other companies that are similar to Nektar Therapeutics include Omeros, Assembly Biosciences, Cumberland Pharmaceuticals, Organigram and ProQR Therapeutics. Learn More about companies similar to Nektar Therapeutics.
How do I contact Nektar Therapeutics' investor relations team?: Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 482-5300 and its investor relations email address is invest[email protected]. The official website for Nektar Therapeutics is www.nektar.com. Learn More about contacing Nektar Therapeutics investor relations.

Nektar Therapeutics - NKTR Stock Price Target and Predictions

Analyst Price Target for NKTR

Current Consensus is Reduce

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.76 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

What is the current price target for Nektar Therapeutics?

What is the current consensus analyst rating for Nektar Therapeutics?

What other companies compete with Nektar Therapeutics?

How do I contact Nektar Therapeutics' investor relations team?